[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA39896A - Nouveaux anticorps antii-rnf43 et méthodes d'utilisation - Google Patents

Nouveaux anticorps antii-rnf43 et méthodes d'utilisation

Info

Publication number
MA39896A
MA39896A MA039896A MA39896A MA39896A MA 39896 A MA39896 A MA 39896A MA 039896 A MA039896 A MA 039896A MA 39896 A MA39896 A MA 39896A MA 39896 A MA39896 A MA 39896A
Authority
MA
Morocco
Prior art keywords
methods
novel anti
rnf43 antibodies
rnf43
antibodies
Prior art date
Application number
MA039896A
Other languages
English (en)
Inventor
Monette Aujay
Mandy Boontanrart
Scott J Dylla
David Liu
Deepti Rokkam
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of MA39896A publication Critical patent/MA39896A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouveaux anticorps anti-rnf43 et des dérivés de ceux-ci, comprenant des conjugués anticorps-médicaments, et des méthodes d'utilisation de tels anticorps anti-rnf43 et conjugués anticorps-médicaments pour diagnostiquer et traiter le cancer.
MA039896A 2014-04-21 2015-04-21 Nouveaux anticorps antii-rnf43 et méthodes d'utilisation MA39896A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461982294P 2014-04-21 2014-04-21

Publications (1)

Publication Number Publication Date
MA39896A true MA39896A (fr) 2017-03-01

Family

ID=54333409

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039896A MA39896A (fr) 2014-04-21 2015-04-21 Nouveaux anticorps antii-rnf43 et méthodes d'utilisation

Country Status (18)

Country Link
US (1) US20170073430A1 (fr)
EP (1) EP3134121A4 (fr)
JP (1) JP2017518040A (fr)
KR (1) KR20170010764A (fr)
CN (1) CN106714831A (fr)
AU (1) AU2015249887A1 (fr)
BR (1) BR112016024525A2 (fr)
CA (1) CA2946308A1 (fr)
CL (2) CL2016002667A1 (fr)
CR (1) CR20160486A (fr)
DO (1) DOP2016000283A (fr)
EA (1) EA201692100A8 (fr)
IL (1) IL248399A0 (fr)
MA (1) MA39896A (fr)
MX (1) MX2016013857A (fr)
PH (1) PH12016502061A1 (fr)
SG (1) SG11201608715WA (fr)
WO (1) WO2015164392A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI807362B (zh) 2010-11-30 2023-07-01 日商中外製藥股份有限公司 細胞傷害誘導治療劑
US20190194319A1 (en) * 2016-05-20 2019-06-27 Abbvie Stemcentrx Llc Anti-ascl1 antibodies and methods of use
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
US11958891B2 (en) 2017-01-26 2024-04-16 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
EP3619238A4 (fr) * 2017-05-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique induisant une cytotoxicité
EP3765054A4 (fr) * 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania Compositions et méthodes de ciblage de lymphocytes t gamma delta au moyen de récepteurs antigéniques chimériques
CN112654363A (zh) * 2018-07-09 2021-04-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
EP3877399A4 (fr) * 2018-11-06 2022-10-19 Alsatech, Inc. Thérapie génique de maladies neurodégénératives à base de cellules
US11713461B2 (en) 2019-06-21 2023-08-01 Regeneran Pharmaceuticals, Inc. Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors
WO2022109443A1 (fr) * 2020-11-23 2022-05-27 The Regents Of The University Of Michigan Anticorps à chaîne unique contre la protéine ns1 de flavivirus
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
EP4288458A1 (fr) * 2021-02-03 2023-12-13 Genentech, Inc. Plateforme de dégradation de protéines de liaison multispécifiques et méthodes d'utilisation
JP2024510291A (ja) * 2021-03-16 2024-03-06 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫疾患を治療するための二機能性分子
CN113372447A (zh) * 2021-05-26 2021-09-10 重庆中元汇吉生物技术有限公司 抗pivka-ii单克隆抗体及其应用
WO2024025878A2 (fr) * 2022-07-25 2024-02-01 Memorial Sloan-Kettering Cancer Center Procédés de préparation pour thérapies cellulaires adoptives
CN117801108B (zh) * 2023-12-06 2024-06-07 无锡傲锐东源生物科技有限公司 抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613405A (zh) * 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 与人结肠癌相关的基因和多肽
RS54163B1 (en) * 2006-05-30 2015-12-31 Genentech Inc. ANTI-CD22 ANTIBODIES, THEIR IMMUNCONJUGATES AND THEIR USE
ES2769786T3 (es) * 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
US20150125857A1 (en) * 2012-02-28 2015-05-07 Novartis Ag CANCER PATIENT SELECTION FOR ADMINISTRATION OF Wnt SIGNALING INHIBITORS USING RNF43 MUTATION STATUS

Also Published As

Publication number Publication date
CL2017003240A1 (es) 2018-06-01
JP2017518040A (ja) 2017-07-06
US20170073430A1 (en) 2017-03-16
SG11201608715WA (en) 2016-11-29
EA201692100A8 (ru) 2018-11-30
KR20170010764A (ko) 2017-02-01
BR112016024525A2 (pt) 2017-10-10
AU2015249887A1 (en) 2016-11-03
DOP2016000283A (es) 2016-11-30
CN106714831A (zh) 2017-05-24
WO2015164392A2 (fr) 2015-10-29
CL2016002667A1 (es) 2017-07-07
EA201692100A1 (ru) 2017-02-28
WO2015164392A3 (fr) 2015-12-23
EP3134121A2 (fr) 2017-03-01
EP3134121A4 (fr) 2017-11-08
PH12016502061A1 (en) 2016-12-19
MX2016013857A (es) 2017-07-14
IL248399A0 (en) 2016-11-30
CR20160486A (es) 2017-02-20
CA2946308A1 (fr) 2015-10-29
WO2015164392A8 (fr) 2016-12-29

Similar Documents

Publication Publication Date Title
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
TN2015000396A1 (en) Antibody drug conjugates
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
MD20170032A2 (ro) Anticorpi anti-TIGIT
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2019004690A (es) Constructos de anticuerpos.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
TN2016000472A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.